Catalysts / CAPR
Upcoming FDA decisions and readouts we track for Capricor Therapeutics, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Capricor Therapeutics (CAPR, listed on Nasdaq). It concerns Deramiocel (Duchenne muscular dystrophy cardiomyopathy).
First on the list: the PDUFA date (extended) for Deramiocel (Duchenne muscular dystrophy cardiomyopathy), dated 22 Nov 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Capricor Therapeutics CAPR · Nasdaq | Deramiocel | Duchenne muscular dystrophy cardiomyopathy | 22 Nov 2026 in 46d |
PDUFA date (extended) | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList